← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Accelevir Diagnostics, Llc
Baltimore, MD
$13,493,911
Total funding
13
Grants
Funding over time
peak $3.5M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,293,930 · 12
NSF$1,199,981 · 1
By mechanism
U24$4,893,393 · 1
R43$2,345,262 · 7
R44$2,000,000 · 1
N44$2,000,000 · 1
—$1,199,981 · 1
R24$755,300 · 1
Investigators at Accelevir Diagnostics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Proviral Sequencing Driven Development of Enhanced IPDAv2 with Global HIV-1 Group M Coverage to Support Worldwide Cure and Clinical Trials$2,000,000
N44 · FY2023 · AI
Centralized Resource to Accurately Quantify Latent and Expressed HIV Reservoirs$1,476,344
U24 · FY2023 · AI
SBIR Phase II: Development and Optimization of a New Molecular Test to quantify Latent HIV-1 in Samples from HIV-1 Infected Individuals.$1,199,981
· FY2017 · TIP
Centralized Resource to Accurately Quantify Latent and Expressed HIV Reservoirs$1,167,880
U24 · FY2022 · AI
A Novel Test to Measure Latent Virus in HIV-1 Infected Patients$1,000,000
R44 · FY2018 · AI
A Novel Test to Measure Latent Virus in HIV-1 Infected Patients$1,000,000
R44 · FY2019 · AI
Centralized Resource to Accurately Quantify Latent and Expressed HIVReservoirs$755,300
R24 · FY2025 · AI
Centralized Resource to Accurately Quantify Latent and Expressed HIV Reservoirs$749,993
U24 · FY2020 · AI
Centralized Resource to Accurately Quantify Latent and Expressed HIV Reservoirs$749,588
U24 · FY2021 · AI
Centralized Resource to Accurately Quantify Latent and Expressed HIV Reservoirs$749,588
U24 · FY2024 · AI
IPDA for High-Priority HIV-1 Subtype C to Enable Global Eradication Trials$300,000
R43 · FY2021 · AI
IPDA for High-Priority HIV-1 Subtype C to Enable Global Eradication Trials$300,000
R43 · FY2022 · AI
Development of Intact Proviral DNA Assays for SIV and SHIV$300,000
R43 · FY2020 · AI
HIV-1 EnvLRS: a scalable, sequence-based assay for in-depth assessment of HIV-1 bNAb resistance$300,000
R43 · FY2021 · AI
Development of a quantitative assay for intact HIV DNA measures in tissue$300,000
R43 · FY2018 · AI
IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials$299,975
N43 · FY2020 · AI
Development of a next-generation quantitative viral outgrowth assay (QVOA) for the standardized measurement of the HIV-1 latent reservoir$297,200
R43 · FY2017 · AI
Highly specific HIV-1 mRNA detection method with global subtype coverage to monitor latency reversal in patients$288,740
R43 · FY2017 · AI
A Novel Test to Measure Latent Virus in HIV-1 Infected Patients$259,322
R43 · FY2016 · AI